Highlights on cabozantinib with nivo and ipi for intermediate_poor risk adv. RCC_COSMIC-313

• Date : 2022-09-14
• 21    
  1

Highlights on ADT duration with post-operative radiotherapy in prostate cancer_RADICALS-HD

• Date : 2022-09-14
• 16    
  0

Highlights on first-line atezolizumab in NSCLC not eligible for platinum_ The IPSOS study

• Date : 2022-09-14
• 15    
  0

Highlights on Sotorasib in NSCLC with KRAS G12C mutation_ The CodeBreaK 200 study

• Date : 2022-09-14
• 9    
  0

Highlights on neoadj. vs adjuvant pembrolizumab in resected stage III-IV melanoma_SWOG S1801

• Date : 2022-09-14
• 8    
  0

Highlights on the efficacy and safety of fruquintinib in refractory mCRC_ The FRESCO-2 study

• Date : 2022-09-14
• 8    
  0

Highlights on pembrolizumab with CRT in locally advanced HNSCC_ The KEYNOTE-412 study

• Date : 2022-09-14
• 6    
  0

ESMO Gynaecological Cancers Congress 2024

• Date : 2024-06-20
• 10817    
  0

SIFEM 2024

• Date : 2024-06-13
• 2125    
  0

Annual Meeting on Women's Cancer SGO 2024

• Date : 2024-03-16
• 1913    
  0

43ème Réunion interdisciplinaire de chimiothérapie anti-infectieuse

• Date : 2023-12-18
• 10254    
  0

13e Congrès National des réseaux en Cancérologie - CNRC 2023

• Date : 2023-11-09
• 7348    
  0